Necrotizing fasciitis is a fulminant soft tissue infection characterized by rapid progression and high mortality. Rituximab is a generally well-tolerated immunosuppresive medication used for B-cell malignancies and some rheumatological disorders. We report a case of a 69-year-old male with chronic lymphocytic leukemia who suffered necrotizing fasciitis of his left lower extremity secondary to Clostridium septicum 7 weeks after treatment with rituximab. Despite immediate intravenous antimicrobial therapy and emergent fasciotomy with extensive debridement, his hospital course was complicated by septic shock and he required an above-the-knee amputation. Physicians need to be aware of the possibility of necrotizing fasciitis in patients presenting with skin infections after rituximab therapy.
CITATION STYLE
Abdulkareem, A., D’Souza, R. S., Shogbesan, O., & Donato, A. (2017). A Case of Rituximab-Induced Necrotizing Fasciitis and a Review of the Literature. Case Reports in Hematology, 2017, 1–5. https://doi.org/10.1155/2017/6971027
Mendeley helps you to discover research relevant for your work.